1295P Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS)

Authors :: M. Saggese
Yong He
Wenqian Li
Andrew Walding
Ying Cheng
Qin Zhou
Bu-Hai Wang
H-L. Zhang
Yu-Zhen Liu
S.S. Ramalingam
R. Su
Chunling Liu
X. Huang
Source :: Annals of Oncology. 31:S838-S839
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
First line treatment
medicine.medical_specialty
Egfr tki
business.industry
Internal medicine
medicine
Overall survival
Osimertinib
Hematology
business

Full Text Access

Tools